|
🐜
|
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
48 auth.
Nicholas D. James,
Nicholas D. James,
M. Sydes,
N. Clarke,
M. Mason,
D. Dearnaley,
M. Spears,
A. Ritchie,
C. Parker,
J. Russell,
G. Attard,
J. Bono,
W. Cross,
Robert Jones,
G. Thalmann,
...
C. Amos,
D. Matheson,
R. Millman,
M. Alzouebi,
S. Beesley,
A. Birtle,
S. Brock,
R. Cathomas,
P. Chakraborti,
S. Chowdhury,
A. Cook,
T. Elliott,
J. Gale,
S. Gibbs,
J. Graham,
J. Hetherington,
R. Hughes,
R. Laing,
F. McKinna,
D. McLaren,
J. O’Sullivan,
O. Parikh,
C. Peedell,
A. Protheroe,
A. Robinson,
N. Srihari,
R. Srinivasan,
J. Staffurth,
S. Sundar,
S. Tolan,
D. Tsang,
J. Wagstaff,
M. Parmar
|
10 |
2016 |
10
🐜
|
|
🐜
|
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
47 auth.
N. James,
J. D. de Bono,
M. Spears,
N. Clarke,
M. Mason,
D. Dearnaley,
A. Ritchie,
C. Amos,
C. Gilson,
Robert J. Jones,
D. Matheson,
R. Millman,
G. Attard,
S. Chowdhury,
W. Cross,
...
S. Gillessen,
C. Parker,
M. Russell,
D. Berthold,
C. Brawley,
F. Adab,
San Aung,
A. Birtle,
J. Bowen,
S. Brock,
P. Chakraborti,
C. Ferguson,
J. Gale,
E. Gray,
M. Hingorani,
P. Hoskin,
J. Lester,
Z. Malik,
F. McKinna,
N. McPhail,
J. Money-Kyrle,
J. O’Sullivan,
O. Parikh,
A. Protheroe,
A. Robinson,
N. Srihari,
Carys W Thomas,
J. Wagstaff,
J. Wylie,
A. Zarkar,
M. Parmar,
M. Sydes
|
10 |
2017 |
10
🐜
|
|
🦁
|
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
29 auth.
D. Dearnaley,
I. Syndikus,
H. Mossop,
V. Khoo,
A. Birtle,
D. Bloomfield,
J. Graham,
P. Kirkbride,
J. Logue,
Z. Malik,
J. Money-Kyrle,
J. O’Sullivan,
M. Panades,
C. Parker,
H. Patterson,
...
C. Scrase,
J. Staffurth,
A. Stockdale,
Jean Tremlett,
M. Bidmead,
H. Mayles,
O. Naismith,
C. South,
A. Gao,
C. Cruickshank,
S. Hassan,
J. Pugh,
C. Griffin,
E. Hall
|
9 |
2016 |
9
🦁
|
|
🐜
|
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
44 auth.
David P Gillessen,
Silke Gilson,
C. Jones,
Robert J Langley,
R. Malik,
C. Parker,
N. James,
C. Brawley,
N. Clarke,
A. Hoyle,
Adnan Ali,
A. Ritchie,
G. Attard,
S. Chowdhury,
W. Cross,
...
D. Dearnaley,
S. Gillessen,
C. Gilson,
Robert J. Jones,
R. Langley,
Z. Malik,
M. Mason,
D. Matheson,
R. Millman,
J. Russell,
G. Thalmann,
C. Amos,
R. Alonzi,
A. Bahl,
A. Birtle,
O. Din,
H. Douis,
C. Eswar,
J. Gale,
M. Gannon,
S. Jonnada,
S. Khaksar,
J. Lester,
J. O’Sullivan,
O. Parikh,
I. Pedley,
D. Pudney,
D. Sheehan,
N. Srihari
|
9 |
2018 |
9
🐜
|
|
🦁
|
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.
17 auth.
D. Dearnaley,
M. Sydes,
J. Graham,
E. Aird,
D. Bottomley,
R. Cowan,
R. Huddart,
Chakiath C Jose,
J. Matthews,
J. Millar,
...
A. Moore,
Rachel C. Morgan,
J. Russell,
C. Scrase,
R. Stephens,
I. Syndikus,
M. Parmar
|
9 |
2007 |
9
🦁
|
|
🐜
|
Multiple newly identified loci associated with prostate cancer susceptibility
46 auth.
R. Eeles,
Z. Kote-Jarai,
G. Giles,
A. Olama,
M. Guy,
S. Jugurnauth,
S. Mulholland,
D. Leongamornlert,
S. Edwards,
J. Morrison,
H. Field,
M. Southey,
G. Severi,
J. Donovan,
F. Hamdy,
...
D. Dearnaley,
K. Muir,
Charmaine D. Smith,
Melisa Bagnato,
A. Ardern-jones,
A. Hall,
L. O'Brien,
Beatrice N. Gehr-Swain,
R. Wilkinson,
A. Cox,
S. Lewis,
Paul M. Brown,
S. Jhavar,
M. Tymrakiewicz,
A. Lophatananon,
Sarah L Bryant,
A. Horwich,
R. Huddart,
V. Khoo,
C. Parker,
C. Woodhouse,
A. Thompson,
T. Christmas,
C. Ogden,
C. Fisher,
C. Jamieson,
C. Cooper,
D. English,
J. Hopper,
D. Neal,
D. Easton
|
9 |
2008 |
9
🐜
|
|
🐜
|
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
16 auth.
G. Attard,
A. Reid,
T. Yap,
F. Raynaud,
M. Dowsett,
S. Settatree,
M. Barrett,
C. Parker,
V. Martins,
E. Folkerd,
...
Jeremy Clark,
C. Cooper,
S. Kaye,
D. Dearnaley,
Gloria Lee,
J. D. de Bono
|
9 |
2008 |
9
🐜
|
|
🦁
|
Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial
8 auth.
D. Dearnaley,
V. Khoo,
A. Norman,
L. Meyer,
A. Nahum,
D. Tait,
...
J. Yarnold,
A. Horwich
|
9 |
1999 |
9
🦁
|
|
🐜
|
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
19 auth.
G. Attard,
A. Reid,
R. A’Hern,
Christopher C. Parker,
N. Oommen,
E. Folkerd,
C. Messiou,
L. R. Molife,
G. Maier,
E. Thompson,
...
D. Olmos,
R. Sinha,
Gloria Lee,
M. Dowsett,
S. Kaye,
D. Dearnaley,
T. Kheoh,
A. Molina,
J. D. de Bono
|
9 |
2009 |
9
🐜
|
|
🐜
|
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array
144 auth.
R. Eeles,
A. Olama,
S. Benlloch,
E. Saunders,
D. Leongamornlert,
M. Tymrakiewicz,
M. Ghoussaini,
C. Luccarini,
J. Dennis,
S. Jugurnauth-Little,
Tokhir Dadaev,
D. Neal,
F. Hamdy,
J. Donovan,
K. Muir,
...
G. Giles,
G. Severi,
F. Wiklund,
H. Gronberg,
C. Haiman,
F. Schumacher,
B. Henderson,
L. Marchand,
S. Lindstrom,
P. Kraft,
D. Hunter,
S. Gapstur,
S. Chanock,
S. Berndt,
D. Albanes,
G. Andriole,
J. Schleutker,
Maren Weischer,
F. Canzian,
E. Riboli,
T. Key,
R. Travis,
D. Campa,
S. Ingles,
E. John,
R. Hayes,
P. Pharoah,
N. Pashayan,
K. Khaw,
J. Stanford,
E. Ostrander,
L. Signorello,
S. Thibodeau,
D. Schaid,
C. Maier,
W. Vogel,
A. Kibel,
C. Cybulski,
J. Lubiński,
L. Cannon-Albright,
H. Brenner,
Jong Y. Park,
R. Kaneva,
J. Batra,
A. Spurdle,
J. Clements,
M. Teixeira,
E. Dicks,
Andrew Lee,
A. Dunning,
C. Baynes,
D. Conroy,
M. Maranian,
Shahana Ahmed,
K. Govindasami,
M. Guy,
R. Wilkinson,
E. Sawyer,
A. Morgan,
D. Dearnaley,
A. Horwich,
R. Huddart,
V. Khoo,
C. Parker,
N. V. As,
C. Woodhouse,
A. Thompson,
T. Dudderidge,
C. Ogden,
C. Cooper,
A. Lophatananon,
A. Cox,
M. Southey,
J. Hopper,
D. English,
M. Aly,
J. Adolfsson,
Jiangfeng Xu,
S. Zheng,
M. Yeager,
R. Kaaks,
W. Diver,
M. Gaudet,
M. Stern,
Román Corral,
A. Joshi,
Ahva Shahabi,
Tiina Wahlfors,
T. Tammela,
A. Auvinen,
J. Virtamo,
P. Klarskov,
B. Nordestgaard,
M. Røder,
S. F. Nielsen,
S. Bojesen,
A. Siddiq,
L. FitzGerald,
S. Kolb,
E. Kwon,
D. Karyadi,
W. Blot,
W. Zheng,
Q. Cai,
S. McDonnell,
A. Rinckleb,
B. Drake,
G. Colditz,
D. Wokołorczyk,
R. Stephenson,
C. Teerlink,
H. Muller,
D. Rothenbacher,
T. Sellers,
Hui-Yi Lin,
C. Slavov,
V. Mitev,
F. Lose,
Srilakshmi Srinivasan,
S. Maia,
P. Paulo,
E. Lange,
K. Cooney,
A. Antoniou,
Daniel Vincent,
F. Bacot,
D. Tessier,
Z. Kote-Jarai,
D. Easton
|
9 |
2013 |
9
🐜
|
|
🐜
|
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
24 auth.
G. Attard,
J. Swennenhuis,
D. Olmos,
A. Reid,
Elaine Vickers,
R. A’Hern,
Rianne Levink,
F. Coumans,
J. Moreira,
R. Riisnaes,
...
N. Oommen,
G. Hawche,
C. Jameson,
E. Thompson,
R. Sipkema,
C. Carden,
C. Parker,
D. Dearnaley,
S. Kaye,
C. Cooper,
A. Molina,
M. Cox,
L. Terstappen,
J. D. de Bono
|
9 |
2009 |
9
🐜
|
|
🐜
|
Stereotactic body radiotherapy for oligometastases.
10 auth.
A. Tree,
V. Khoo,
R. Eeles,
Merina Ahmed,
D. Dearnaley,
M. Hawkins,
...
R. Huddart,
C. Nutting,
P. Ostler,
N. Van As
|
8 |
2013 |
8
🐜
|
|
🐜
|
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
20 auth.
N. James,
M. Spears,
N. Clarke,
D. Dearnaley,
J. D. de Bono,
J. Gale,
J. Hetherington,
Peter Hoskin,
Robert J Jones,
R. Laing,
...
J. Lester,
D. McLaren,
Christopher C. Parker,
M. Parmar,
A. Ritchie,
J. Russell,
R. Strebel,
G. Thalmann,
M. Mason,
M. Sydes
|
8 |
2015 |
8
🐜
|
